Tyra Biosciences Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
TYRA$21.00-5.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(18,192) | $(11,880) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 122 | 83 |
| Stock-based compensation | 4,115 | 2,433 |
| Accretion on marketable securities, net | (1,229) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (43) | 1,530 |
| Accounts payable, accrued expenses and other liabilities | (6,906) | (2,022) |
| Right-of-use assets and lease liabilities, net | 105 | 9 |
| Net cash used in operating activities | (22,028) | (9,847) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (11,791) | — |
| Sales and maturities of marketable securities | 30,000 | — |
| Purchases of property and equipment | (136) | (41) |
| Net cash provided by (used in) investing activities | 18,073 | (41) |
| Cash flows from financing activities: | ||
| Proceeds from issuances of common stock under benefit plans | 484 | 376 |
| Proceeds from issuance of common stock and pre-funded warrants from Private Placement | 200,000 | — |
| Payments of issuance costs for common stock and pre-funded warrants from Private Placement | (169) | — |
| Net cash provided by financing activities | 200,315 | 376 |
| Net cash increase (decrease) for the period | 196,360 | (9,512) |
| Cash, cash equivalents and restricted cash at beginning of the period | 59,006 | 252,213 |
| Cash, cash equivalents and restricted cash at end of the period | $255,366 | $242,701 |
| Reconciliation of cash, cash equivalents and restricted cash to the balance sheet | ||
| Cash and cash equivalents | $254,366 | $241,701 |
| Restricted cash | 1,000 | 1,000 |
| Total cash, cash equivalents and restricted cash | $255,366 | $242,701 |
| Supplemental disclosure of cash flow information: | ||
| Non-cash investing and financing activities: | ||
| Purchases of equipment included in accounts payable and accrued and other current liabilities | $9 | $— |
| Vesting of options early exercised subject to repurchase | $17 | $32 |
| Issuance costs for common stock and pre-funded warrants from Private Placement included in accounts payable and accrued liabilities | $251 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.